Dr Reddys Laboratories Ltd News

Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Dr Reddy's Laboratories launches generic Semaglutide injection in Canada

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1

4 reasons why analysts are bearish on Dr Reddy's Labs outlook after Q4

Analysts have turned cautious on Dr Reddy's Laboratories after Q4 results raised concerns over weakening US business, sharp Revlimid decline, pricing pressure and delays in semaglutide launches

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market

The fall was driven by weak US sales of Revlimid, offset only partially by growth in India, Europe, and emerging markets

Dr Reddy's Q4 results: PAT down 86% at ₹221 crore, revenue drops 11.51%

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales in North America. The company had posted a profit after tax of Rs 1,586.7 crore in the corresponding quarter previous fiscal year, Dr Reddy's Laboratories Ltd said in a regulatory filing. Consolidated total revenue from operations in the fourth quarter stood at Rs 7,546.4 crore as against Rs 8,528.4 crore in the same period a year ago, it added. Revenue from generic drugs in North America in the quarter was down 51 per cent at Rs 1,756.2 crore as compared to Rs 3,558.6 crore in the year-ago period. On the other hand generics revenue in India grew 20 per cent at Rs 1,566.3 crore as compared to Rs 1,304.7 crore in the corresponding period a year ago, the company said. Similarly, generics revenue in Europe grew by 14 per cent to Rs 1,452 crore from Rs 1,275 crore in the year ago period.

Q4 results: Dr Reddy's, Tata Power, Pfizer, Kalpataru among 104 on May 12

Q4FY26 company results: Firms including Berger Paints, Torrent Power, Max Financial Services, Nazara Technologies, and Vinati Organics are also to release their January-March earnings today

Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Axis Bank, Voda Idea: 28 Nifty 500 stocks reclaim 200-DMA today; full list

Among others Dr. Reddy's, Apollo Hospitals, M&M Finance, Muthoot Finance, Tata Power, Balrampur Chini and Sammaan Capital soared up to 20% from recent lows to cross the long-term average, shows data.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Analyst suggests Nifty strategy; bets on Oil India, Dr Reddy's Labs

Ajit Mishra of Religare Broking recommends Nifty strategy and two stocks to buy; check details here

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Stocks to Watch today: UltraTech Cement, Dr Reddy's Labs, Tata Power, GNFC

Stocks to Watch today, March 9, 2026: HDFC Life Insurance, Tata Power, GNFC, Avenue Supermarts, and Meesho are among the top stocks to remain in focus today

Stocks to Watch: OMCs, Garden Reach, Petronet LNG, JK Tyre, DCX Systems

Stocks to Watch today: OMCs, Garden Reach, Petronet LNG, SAMHI Hotels, DCX Systems, JK Tyre and Dr Reddy's are among the stocks to watch today, March 06, 2026